BridgeBio Secures $300 Million Royalty Financing to Support ATTR-CM Drug Launch
核心洞察
BridgeBio Pharma secured $300 million in upfront financing by selling 60% of European royalties for BEYONTTRA to HealthCare Royalty (搜索) and Blue Owl Capital (搜索).
The transaction monetizes royalties on the first $500 million of annual BEYONTTRA net sales in Europe with a 1.45x cap on total investor payments.
Acoramidis demonstrated rapid clinical benefits in Phase 3 trials, showing 42% reduction in cardiovascular events and 50% reduction in cardiovascular hospitalizations.
BridgeBio Pharma has secured $300 million in non-dilutive financing through a strategic royalty monetization agreement with HealthCare Royalty (搜索) and Blue Owl Capital (搜索), providing immediate capital to support the launch of its newly approved ATTR-CM (搜索) treatment and late-stage pipeline programs.
Strategic Financing Structure
The transaction involves BridgeBio selling 60% of its European royalties for BEYONTTRA on the first $500 million of annual net sales to the investment partners. The agreement includes a 1.45x cap on total payments to investors, meaning once this threshold is reached, no further payments will be owed.
"We're excited to partner with HCRx and Blue Owl to strengthen our balance sheet in support of the launch of Attruby and our pipeline of first and best-in-class genetic medicines," said Chinmay Shukla, Senior Vice President of Strategic Finance at BridgeBio. "This transaction preserves significant upside for our shareholders, with careful structuring that limits annual as well as total payments made to the royalty investors."
Clinical Performance and Regulatory Approvals
Acoramidis demonstrated exceptional clinical performance in the ATTRibute-CM Phase 3 study, showing the most rapid benefit seen in any Phase 3 study of ATTR-CM (搜索) to date. The drug achieved significant clinical milestones across both variant and wild-type ATTR-CM patients:
- Time to first event (all-cause mortality or cardiovascular hospitalization) durably separated from placebo in as few as 3 months
- 42% reduction in composite all-cause mortality and recurrent cardiovascular hospitalization events relative to placebo at Month 30
- 50% reduction in the cumulative frequency of cardiovascular hospitalization events relative to placebo at Month 30
The drug has received regulatory approval across multiple jurisdictions. Acoramidis is approved as Attruby by the U.S. FDA and as BEYONTTRA by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and UK Medicines and Healthcare Products Regulatory Agency. All regulatory labels specify near-complete stabilization of transthyretin (搜索) (TTR (搜索)).
Commercial Partnership and Revenue Potential
BridgeBio previously entered into an exclusive licensing agreement with Bayer Consumer Care AG in March 2024 to commercialize BEYONTTRA in Europe for ATTR-CM (搜索) treatment. Under this partnership, BridgeBio has already received $210 million in upfront and regulatory milestone payments, with an additional $75 million in near-term milestones anticipated. The company will also receive tiered royalties starting in the low-30% range on European net sales.
Investor Confidence and Market Potential
The financing reflects strong investor confidence in acoramidis' commercial potential. Clarke Futch, Chairman and CEO of HealthCare Royalty (搜索), stated: "We have been following the progress of acoramidis for years and strongly believe in its potential to positively impact the lives of patients living with ATTR-CM (搜索)."
Sandip Agarwala, Managing Director and Head of Life Sciences at Blue Owl, added: "This investment reflects our confidence in BEYONTTRA commercial potential and our commitment to providing flexible capital solutions that help advance life-saving therapies."
Drug Profile and Safety
BEYONTTRA functions as an orally administered near-complete (≥90%) stabilizer of transthyretin (搜索), indicated for treating wild-type or variant transthyretin amyloidosis (搜索) in adult patients with cardiomyopathy (搜索). The drug's safety profile in clinical trials showed manageable adverse events, with diarrhea (11.6% vs 7.6% placebo) and upper abdominal pain (5.5% vs 1.4% placebo) being the most common. Discontinuation rates due to adverse events were similar between treatment and placebo groups (9.3% and 8.5%, respectively).